Longeveron Inc. (Class A) (LGVN) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, LGVN carries an RQD Score of 27 out of 100, a letter grade of E, and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are scored as follows: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 3/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).

For a prospective investor evaluating the stock today, the rating points to weakness across nearly every pillar. The cash engine score reflects a negative ROIC of -35% and a 0% FCF yield, meaning the business is not currently generating returns on capital or free cash for shareholders. The lowest pillar scores, insider conviction and whale flow at 3/20 each, indicate limited evidence of informed buying from insiders or large institutions. The forensic balance sheet score of 8/20 combines an Altman Z of 2.5 with a Piotroski F of 3 out of 9, which signals weak fundamental quality. Upside drivers would need to come from outside the current financial profile, such as clinical or regulatory developments; the rating itself does not identify such a driver. Valuation tradeoffs are difficult to assess because standard earnings-based multiples are unavailable in the source data. Per the Roarable RQD rating, the overall posture is a strong sell with a forensic risk flag.

Longeveron Inc. (Class A) (LGVN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Not available in source data for product details, customer base, or specific revenue mechanics. Per the SEC financials, FY 2025 revenue was $1.2M against FY 2024 revenue of $2.4M and FY 2023 revenue of $0.7M. Per the market data section, gross margin is 67%.

Per the market data section, operating margin and net margin are each -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Cash declined from $19.2M in FY 2024 to $4.7M in FY 2025 per the SEC financials. Debt is reported as N/A in each period.

Per the recent news section, the headlines include a BioSpace report titled "Significant stock movers of September: Viking soars, Longeveron slides" (flagged CATALYST, GREEN), a Yahoo! Finance Canada item titled "Longeveron Announces Engagement of Lucid Capital Markets" (MARKET WIRE, YELLOW), a Form 4 filing item from Investing.com UK (MARKET WIRE, YELLOW), a TradingView item noting an LGVN Q3'26 revenue estimate of 563.50K USD (MARKET WIRE, YELLOW), a Stock Titan item headlined "An infant heart trial recorded 8 major events with standard care, 1 with experimental cell therapy. It missed its main goal." (CATALYST, GREEN), and a marketscreener.com item on updated results from the Elpis II Phase 2B trial evaluating laromestrocel for Hypoplastic Left Heart Syndrome (MARKET WIRE, YELLOW). The trial item flagged as missing its main goal is a material risk watch item. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

• What are the specific primary and secondary endpoints of the Elpis II trial, and what does "missed its main goal" mean for the program's next regulatory steps?
• What is the company's cash runway given cash of $4.7M against an FY 2025 FCF of $-18.9M?
• Is there disclosed debt, given that the debt field is N/A across all reported periods while Debt/Equity is listed at 0.5?
• What is the source and timing of the reported Q3'26 revenue estimate of 563.50K USD relative to trailing revenue?
• Why are FY 2023 cash and debt unavailable in the source data, and how does the missing EPS series affect valuation analysis?